An effective combined therapy of meglumine antimoniate and co-trimoxazole for cutaneous leishmaniasis: A study in Quetta City
Keywords:
Cutaneous leishmaniasis, meglumine antimoniate, co-trimoxazole, combined therapyAbstract
Objective To evaluate the efficacy of combined therapy of meglumine antimoniate and co-trimoxazole in cutaneous leishmaniasis (CL). Methods 180 patients with active lesions of CL, confirmed by fine needle aspiration cytology (FNAC) were treated with combined therapy of meglumine antimoniate (Glucantime) and co-trimoxazole (Septran) for 20 days. Results Out of 180 patients, 160 (88.9%) were cured. A few patients reported nausea, vomiting, glossitis, skin rashes and folate deficiency. Conclusion The combined therapy of meglumine antimoniate (Glucantime) and co-trimoxazole (Septran) is more effective than the previously reported combined therapies.ÂReferences
Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infectious Diseases. 2007;7:581-6.
Bhutto AM, Soomro RA, Nonaka S, Hashiguchi Y. Detection of new endemic areas of cutaneous leishmaniasis in Pakistan: a 6-year study. Int J Dermatol. 2003;42:543-8.
Burney MI, Lari FA. Status of Cutaneous Leishmaniasis in Pakistan. J Pak Med Assoc. 1986;25:101-8.
Pearson RD, Querez AS. Leishmania species: visceral (kala-azar), cutaneous, and mucosal leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone; 1995. pp. 2428-42.
Alvar J, Velez ID, Bern C et al. Leishmaniasis worldwide and global estimates of its incidence. PloS One. 2012;7:35671–2
Herwaldt BL. Leishmaniasis. Lancet. 1999;354:1191-9.
Ghazi RR, Ali R. Cutaneous leishmaniasis in Uthal, Balochistan with a note on its status in Pakistan. Proc Parasitol. 1998;5:40-5.
Rowland M, Munir A, Durrani N et al. An outbreak of cutaneous leishmaniasis in an Afghan refugee settlement in North West Pakistan. Trans Roy Soc Trop Med Hyg. 1999;93:133-6.
Juma KK. Present situation of cutaneous leishmaniasis in Balochistan, Pakistan. Pak J Biol Sci. 2004;7;698-702
Fereidoun A, Mohsen J, Hossein H. Epidemiology and Control of Common Disorders in Iran, 3rd Edi. Tehran: Khosravi Pub; 2009.
Murray HW, epin JP, TB, Nutman SL et al. Recent advances: tropical medicine. Br Med J. 2000;320:490-4.
Ayub S, Gramiccia M, Khalid M et al. Cutaneous leishmaniasis in Multan: species identification. J Pak Med Assoc. 2003;53:445-7.
Jaffernay M, Nighat R. Cutaneous leishmaniasis in Pakistan. Int J Dermatol. 2001;40:159.
Kolaczinski J, Brooker S, Reyburn H, Rowland M. Epidemiology of anthroponotic cutaneous leishmaniasis in Afghan refugee camps in northwest Pakistan. Trans R Soc Trop Med Hyg. 2004;98:373-8.
Juma KK. Kaal Daana (Cutaneous Leishmaniasis) in South-West Pakistan: A preliminary study. Türkiye Parazitoloji Dergisi. 2004;28:5-11.
Munir A, Janjua SA, Hussain I. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis. Acta Dermatovenerol Croat. 2008;16:60-4.
Samuel M, Joseph MJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med. 1992;326:741-4.
Miranda-Verastegui C, Tulliano G, Gyorkos TW et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis. 2009;3:e491.
WHO Control of Leishmaniasis. WHO Technical report series No 793; 1990.
